Ecabet Sodium의 추가가 Helicobacter pylori 일차 삼제 요법의 제균율에 미치는 효과 = Effect of Additional Ecabet Sodium on Conventional Triple Therapy for Helicobacter pylori Eradication in Korea

다국어 초록 (Multilingual Abstract)

Background/Aims: Ecabet sodium is known for its bactericidal effect against H. pylori. It was reported that a supplement of ecabet sodium to conventional triple therapy showed good results in Asia. The Aim of this study was to ascertain the efficacy of additional ecabet sodium on conventional triple therapy for eradication of H. pylori.
Methods: We reviewed the cases of 111 patients (Group A) with H. pylori infection who received ecabet sodium with triple therapy (20 mg of rabeprazole, 1 g of amoxicillin, 500 mg of clarithromycin and 1 g of ecabet sodium, twice daily for 7 days). Another 186 patients (Group B) received PPI-based triple therapy (same as the above, except without the ecabet sodium). Eradication was evaluated 4 weeks later after completion of treatment by ^(13)C-UBT.
Results: Eradication rates were 74.8% (83/111) in group A and 70.4% (131/186) in group B by intention-to-treat analysis (p=0.420), and 75.2% (82/109) in group A and 70.7% (128/181) in group B by per protocol analysis (p=0.405).
Conclusions: The addition of ecabet sodium to conventional triple therapy did not increase the eradication rate of H. pylori in this study. These findings imply that ecabet sodium as an additional agent cannot overcome antibiotic resistance, which is the most important cause of failure of triple therapy.

국문 초록 (Abstract)

목적: Ecabet sodium은 Helicobacter pylori에 대하여 항균성을 가지고 있다. 최근 아시아에서 ecabet sodium을 기존의 프로톤펌프 억제제를 기반으로 하는 삼제 요법에 추가하여 제균율을 증가시켰다는 보고들이 있다. 본 연구에서는 한국인 환자에서 ecabet sodium을 삼제 요법에 추가하여 H. pylori의 제균율에 대한 영향을 확인하고자 하였다.
대상 및 방법: H. pylori에 감염된 환자들 중 111명은 기존의 삼제요법에 ecabet sodium을 추가하여 치료하였고(rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, ecabet sodium 1 g, 1일 2회, 7일 간)(Group A), 186명은 삼제 요법으로 치료하였다(rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, 1일 2회, 7일간)(Group B). 투약이 완료된 4주 뒤에 제균 여부를 ^(13)C-요소 호기 검사로 확인하였다.
결과: 결과는 후향적으로 분석하였고, 제균율은 intention to treat 분석 시 Group A에서 74.8%(83/111)였고, Group B에서 70.4%(131/186)(p=0.420)이었다. Per protocol 분석 시에는 Group A에서 75.2%(82/109)였고, Group B에서 70.7%(128/ 181)(p=0.405)이었다.
결론: 본 연구에서는 Ecabet sodium을 기존의 프로톤펌프 억제제를 기반으로 하는 삼제 요법에 추가하여도 제균율이 증가하지 않았다. 이것은 ecabet sodium의 추가가 최근의 항생제 내성을 극복하지 못한 것으로 생각된다.

참고문헌 (Reference)

1 김정목, "한국인 환자에서 분리한 Helicobacter pylori 균주의 항생제 내성률" 대한소화기학회 47 (47): 337-349, 2006

2 남택만, "소화성 궤양 환자에서 표준 삼제요법에 의한 Helicobacter pylori 제균 성적에 영향을 미치는 임상 인자" 대한소화기내시경학회 36 (36): 200-205, 2008

3 Méegraud F. H, "pylori antibiotic resistance: prevalence, importance, and advances in testing" 53 : 1374-1384, 2004

4 Lee KH, "Triple therapy for eradication of H. pylori in patients with peptic ulcer" 31 : 605-614, 1998

5 Egan BJ, "Treatment of Helicobacter pylori infection" 13 (13): 35S-40S, 2008

6 Gao W, "The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China" 15 : 460-466, 2010

7 Fock KM, "Second Asia-Pacific consensus guidelines for Helicobacter pylori infection" 24 : 1587-1600, 2009

8 Broutet N, "Risk factors for failure of Helicobacter pylori therapy: results of an individual data analysis of 2751 patients" 17 : 99-109, 2003

9 Meyer JM, "Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999" 136 : 13-24, 2002

10 Kim BW, "Pooled analysis of antibiotic therapy for Helicobacter pylori eradication in Korea" 34 : 42-49, 1999

11 Correa P, "Natural history of Helicobacter pylori infection" 40 : 490-496, 2008

12 Kim N, "Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea" 40 : 683-687, 2006

13 최유식, "Helicobacter pylori 일차 삼제 제균요법의 연도별 제균율 분석: 단일 기관의 최근 8년 성적" 대한소화기학회 48 (48): 156-161, 2006

14 Graham DY, "Helicobacter pylori treatment in the era of increasing antibiotic resistance" 59 : 1143-1153, 2010

15 De Bortoli N, "Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics" 102 : 951-956, 2007

16 Peek RM, "Helicobacter pylori and gastrointestinal tract adenocarcinomas" 2 : 28-37, 2002

17 Marshall BJ, "Helicobacter pylori" 89 (89): 116S-128S, 1994

18 Kim H, "H pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium" 14 : 908-912, 2008

19 Asaka M, "Guidelines in the management of Helicobacter pylori infection in Japan" 6 : 177-186, 2001

20 Blaser MJ, "Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease" 93 : 371-383, 1987

21 Glupczynski Y, "European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori" 20 : 820-823, 2001

22 Chung WC, "Eradication rate of Helicobacter pylori according to the diseases and therapeutic regimens, and reinfection rate after successful eradication in a tertiary clinic" 41 : 1-8, 2003

23 Fock KM, "Epidemiology of Helicobacter pylori infection and gastric cancer in Asia" 25 : 479-486, 2010

24 Adachi K, "Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen" 15 : 1187-1191, 2001

25 Ito Y, "Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. II. Interaction with substrate protein" 62 : 175-181, 1993

26 Onoda Y, "Effects of the new anti-ulcer agent 12-sulfodehydroabietic acid monosodium salt on duodenal alkaline secretion in rats" 40 : 576-578, 1990

27 Lee KM, "Effect of one-week triple therapy of ranitidine bismuth citrate, amoxicillin and clarithromycin in Helicobacter pylori-related peptic ulcer patients" 37 : 412-417, 2001

28 김정목, "Ecabet sodium이 Helicobacter pylori에 감염된 인체 위상피세포에서의핵전사인자 활성과 chemokine 유전자 발현에 미치는 영향" 대한내과학회 65 (65): 178-187, 2003

29 Ito Y, "Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori" 345 : 193-198, 1998

30 Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report" 56 : 772-781, 2007

31 Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report" 16 : 167-180, 2002

32 Kobayashi I, "Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005" 45 : 4006-4010, 2007

33 Shibata K, "Bactericidal effect of ecabet sodium on clarithromycin- and metronidazole-resistant clinical isolates of Helicobacter pylori" 50 : 525-531, 1997

34 Shibata K, "Bactericidal activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori Under acidic conditions" 39 : 1295-1299, 1995

35 Sherman PM, "Appropriate strategies for testing and treating Helicobacter pylori in children: when and how?" 117 (117): 30S-35S, 2004

36 Chuang CH, "Adjuvant effect of vitamin C on omeprazole-amoxicillin-clarithromycin triple therapy for Helicobacter pylori eradication" 54 : 320-324, 2007

37 Gisbert JP, ""Rescue" regimens after Helicobacter pylori treatment failure" 14 : 5385-5402, 2008